The clinical trial involving 251 pediatric patients proved the efficacy of the syrup administered within the first 24 hours of the onset of symptoms
The trial confirmed that using Bimunal:
Rhinorrhea was reduced on the first day already in a group of children who were using the syrup, Bimunal, to boost their immunity and suppress the virus. After five days, nearly 30% of the children had a lesser symptom of rhinorrhea than children in the group which did not use the syrup. By the tenth day, the symptom of a runny nose was reduced in 90% of the children in the group which was using Bimunal. Overall, there were 3 times fewer children who still had a symptom of rhinorrhea in the group of children who were using the syrup compared to the group of children who were not using the syrup.
Sore throat was present as a symptom in all children who were tested during the clinical trial. The children who received Bimunal as therapy began to feel relief from the very first days. On the fifth day, more than half of the children in the group of children who were not using Bimunal still had sore throats, and in the group of children who were using the syrup, there were only about 20% compared to their number at the onset of the viral infection. On the tenth day, children who were using Bimunal almost had no sore throat at all, while a quarter of children who were not using it were still in pain. The percentage of the reduction of symptoms by using the syrup was even 97%.
Cough is probably the most persistent symptom compared to the other symptoms of respiratory infections. Sometimes it even lasts a couple of weeks. As the examinations during the clinical trial showed, Bimunal influenced its reduction as well. The number of children coughing in the group of children who were taking Bimunal was 30% lower on the fifth day compared to the other group. On the tenth day, 2,4 times fewer children were coughing, thus a reduction of 70% was observed.
High fever was also reduced more rapidly in the group of children who were using Bimunal. It was recorded in the group of children who were using the syrup that all children who had a fever at the onset of the viral infection on the day five no longer had it. In the control group, the temperature was lower on the fifth day, but it was still not in the normal range. The decrease in body temperature was statistically significantly higher in children who were treated with Bimunal, 1.03 ° C compared to 0.5 ° C in the control group.
The use of antipyretics (paracetamol and brufen) was observed in a significantly lower percentage in the group of children who were using Bimunal since the first day of the viral infection. On the first day in this group, antipyretics were less used for 15%, and on the fifth day, their usage was two times less than in the control group. Although antipyretics were used more in the control group, the body temperature in children was higher.
The use of local vasoconstrictors, antihistamines, and antitussives, or different nasal drops, was already 26% lower in the group of children who were using Bimunal from the first day of the onset of the viral infection. For the first five days, they were administered even 4x less in the group of children who were using Bimunal compared to the control group. By the tenth day, this therapy was almost completely disregarded.
The use of antibiotics was observed in a much smaller percentage in the group of children who were using Bimunal during the course of the viral respiratory infection. While in the control group of the children the antibiotic was prescribed on the fifth day as expected in relation to the symptoms, in the group which was using Bimunal, the antibiotic was used 2.5 times less. On the tenth day, half the children who were using Bimunal were using the antibiotic as well.
During the study, the patients were examined three times – at the beginning of the disease, on the fifth day, and after ten days. The examination included demographic information, weight and height, medical history, physical examination, and laboratory analysis for parameters: sedimentation, blood count, CPR. The first group of children was using Bimunal from day one, and the second (control) group was not using it at all.
An open-label multicenter clinical trial:
Prof. Dr Branimir Nestorović, moderator
Prof. Dr Kristina Mironska, co-moderator
Dr sci. med Katarina Milošević, research associate, co-moderator
While in its mother's womb, a baby receives all the nutrients from the mother. After birth, in order to continue healthy growth and development, it must take in nutrients through diet and supplements. Find out what your baby needs from the very birth.Learn More
Follow 4U pharma news